The Tissue Core (CORE C) mandate is to provide a national resource that consists of a dataset of matched samples of frozen cells with corresponding pathological and clinical data. The Tissue Core is an integral and essential component of this proposal since it is the central repository for all samples. It maintains accurate records of the trafficking of all samples and facilitates the uniform sharing of information between all CRC projects. In addition, it facilitates and expedites the research of each CRC project and clinical trials by performing centralized standardized assays and distributing characterized samples to all members of this proposal. This Core ensures the long-term physical integrity of the biospecimen and maintains the privacy and confidentiality of the research participant.
The first aim of this Core is to serve as the central biorepository for all CLL samples diagnosed and collected from the participating clinical sites. This enables the uniform processing, storage, and distribution of all CLL samples used by the investigators of this proposal.
The second aim i s to perform a basic set of standardized assays on all viably stored CLL samples from each patient upon initial receipt, and as required by the clinical protocols.
The third aim i s to acquire serial samples during the disease progression of all CLL patients to enable longitudinal studies on the disease progression. CRC investigators can segregate cases that have indolent and non-progressive disease from those who have progressive disease or from those who have a change in the kinetics of disease progression.
The fourth aim, a multi-site service, is to organize and assure accurate scoring and high quality data entry associated with FISH for CLL among all CRC sites. This service provides reliable cytogenetic data for clinical trials and research correlations. The fifth aim is to characterize CLL samples based on their cellular kinetics. As an adjunct to these studies, the expressed immunoglobulin heavy chain genes (IGHV) about the leukemic clones can then be correlated to cellular kinetics to study the role for (auto) antigen drive in the clonal expansion. Lastly, the sixth aim is to manage the distribution and tracking of specific characterized samples as requested for hypothesis-driven studies of this proposal.

Public Health Relevance

This Core facilitates research designed to translate the findings of basic science into information useful in the clinical arena for CLL patients. It provides a national resource consisting of a dataset of matched samples with corresponding pathological and clinical data. This interactive information on each CLL sample allows for a better understanding of the biology of CLL and improved prognosis and clinical trials for this leukemia.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-0)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Diego
La Jolla
United States
Zip Code
Hasan, M K; Yu, J; Chen, L et al. (2017) Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells. Leukemia 31:2615-2622
Patel, V M; Balakrishnan, K; Douglas, M et al. (2017) Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199). Leukemia 31:1872-1881
Patel, Viralkumar; Balakrishnan, Kumudha; Bibikova, Elena et al. (2017) Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells. Clin Cancer Res 23:3734-3743
Edelmann, J; Tausch, E; Landau, D A et al. (2017) Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial. Leukemia 31:734-738
Miller, Cecelia R; Ruppert, Amy S; Fobare, Sydney et al. (2017) The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia. Oncotarget 8:25942-25954
Vangapandu, Hima V; Jain, Nitin; Gandhi, Varsha (2017) Duvelisib: a phosphoinositide-3 kinase ?/? inhibitor for chronic lymphocytic leukemia. Expert Opin Investig Drugs 26:625-632
Vangapandu, Hima V; Chen, Huiqin; Wierda, William G et al. (2017) Proteomics profiling identifies induction of caveolin-1 in chronic lymphocytic leukemia cells by bone marrow stromal cells. Leuk Lymphoma :1-12
Rassenti, Laura Z; Balatti, Veronica; Ghia, Emanuela M et al. (2017) MicroRNA dysregulation to identify therapeutic target combinations for chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 114:10731-10736
Kipps, Thomas J; Stevenson, Freda K; Wu, Catherine J et al. (2017) Chronic lymphocytic leukaemia. Nat Rev Dis Primers 3:16096
Vangapandu, Hima V; Havranek, Ondrej; Ayres, Mary L et al. (2017) B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic Leukemia. Mol Cancer Res 15:1692-1703

Showing the most recent 10 out of 552 publications